Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mavenclad Poised To Be Big Mover For Merck KGaA

Executive Summary

The German group is predicting sales of its new MS drug Mavenclad in the mid-triple digit million euro range worldwide in 2019 if all goes well across the Atlantic.

You may also be interested in...



Merck KGaA Plays Down Mavenclad Label And $99,500 annual Price For 10 MS Pills

Merck KGaA's multiple sclerosis pill Mavenclad has finally won FDA approval, but some analysts think its US label, stipulating second-line use in relapsing MS but not in patients with clinically isolated syndrome, may hurt its uptake there.

Merck KGaA Expects Core Franchises, Alliances To Strengthen In China

Merck KGaA's healthcare business in China will continue to center around its fertility, general medicines and endocrinology therapies while also building on new corporate alliances there, the German conglomerate’s global operations head told Scrip. 

 

 

 

 
 

Keytruda/Inlyta Data Stoke Competition In Kidney Cancer

Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.


Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel